Non-invasive tests (NITs) have transformed how we identify and manage metabolic liver disease. Yet as MASLD and MASH prevalence continues to rise, the question is no longer whether we can detect disease — but how early, how reliably, and how dynamically we can monitor change.
Our newly published LIVERFASt performance paper, following a rigorous 1.5-year peer-review process, offers important insights into what meaningful performance looks like in real clinical practice.
Strong diagnostic performance — without the grey zone
In a large, multicenter analysis, LIVERFASt demonstrated robust diagnostic accuracy across fibrosis stages, achieving:
- AUROC 0.868 for cirrhosis (F4)
- AUROC 0.846 for advanced fibrosis (≥F3)
- AUROC 0.748 for clinically significant fibrosis (≥F2)
Across all stages, LIVERFASt outperformed FIB-4, particularly at earlier fibrosis thresholds where clinical decision-making is most challenging.
Importantly, LIVERFASt was purpose-built for MASLD/MASH and does not rely on age-dependent transaminases. As a result, it avoids the indeterminate “grey zone” that often complicates interpretation and downstream referrals.
Sensitivity and rule-out confidence where it matters most
Performance metrics only become meaningful when applied to real populations.
At an advanced fibrosis prevalence of 15% — representative of general and primary care settings — LIVERFASt demonstrated:
- 71% sensitivity
- 94% negative predictive value (NPV)
At 35% prevalence, reflective of specialist and tertiary centers, LIVERFASt maintained superior sensitivity and NPV compared with FIB-4.
This translates into nearly twice as many true advanced-fibrosis cases detected, with stronger reassurance when ruling out disease — a critical advantage in large-scale screening and referral pathways.
Designed to work with VCTE, not replace it
LIVERFASt’s performance profile makes it an ideal partner to vibration-controlled transient elastography (VCTE / FibroScan) in a structured two-step pathway.
High sensitivity and NPV at the blood-test level allow clinicians to:
- Screen broadly and confidently
- Reserve imaging for patients most likely to benefit
- Reduce unnecessary referrals and biopsies
An ongoing manuscript led by our clinical team is further evaluating LIVERSTAT/LIVERFASt + VCTE versus FIB-4 + VCTE, using biopsy as the adjudicator — reinforcing the value of pathway-based, not siloed, diagnostics.
Meeting FDA expectations for clinical NITs
For non-invasive tests to support clinical decision-making, they must meet regulatory expectations.
LIVERFASt exceeded the FDA’s minimum AUROC threshold of ≥0.70 across all evaluated fibrosis stages, while maintaining balanced sensitivity and specificity (≥65%).
By contrast, FIB-4 demonstrated:
- Lower sensitivity (37–48%)
- Performance decline in older and metabolically complex patients
- Greater susceptibility to age-related ALT changes
Why monitoring matters: detecting change, not just disease
While cross-sectional accuracy is essential, monitoring response to therapy is increasingly central to MASH care, particularly as disease-modifying treatments emerge.
Early real-world data from patients receiving Resmetirom show that LIVERFASt can detect meaningful biological change within weeks:
- ~20% mean fibrosis reduction detected within 16 weeks
- Significant improvement in steatosis alongside fibrosis
- Clear dose-response signals
- No significant change observed with FIB-4 or VCTE during the same period
Crucially, changes in LIVERFASt scores occurred independently of ALT or ApoA1 fluctuations, confirming that the test reflects tissue remodeling rather than transient biochemical shifts.
From static risk to dynamic disease management
These findings reinforce a key principle:
AUROCs alone are not enough.
For screening, monitoring, and long-term disease management, clinicians need tools that:
- Perform consistently across populations
- Detect disease early
- Track improvement over time
- Support structured clinical pathways
LIVERFASt was designed with this clinical reality in mind — evolving non-invasive testing from static risk estimation to quantitative disease monitoring.
Looking ahead
As MASLD and MASH care continues to evolve, Fibronostics remains committed to working closely with clinical leaders, luminary sites, and research partners to refine how non-invasive tools are applied in practice.
We believe the future of liver care lies not only in detecting disease — but in measuring change, earlier and with confidence.
Read the full publication and related clinical insights.
Read the full publication of Alkhouri N. et al. HERE